title: Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy.
authors.forename: J Loren
authors.initials: JL
authors.lastname: Rosenberg
mesh_terms: D000085:Acetates / Q000008:administration & dosage* / Q000191:economics; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000628:therapy*; D003362:Cost-Benefit Analysis; D003521:Cyclopropanes; D003888:Desensitization, Immunologic / Q000009:adverse effects*; D006801:Humans; D006967:Hypersensitivity / Q000628:therapy*; D000069444:Omalizumab; D011241:Prednisone / Q000008:administration & dosage* / Q000191:economics; D011804:Quinolines / Q000008:administration & dosage* / Q000191:economics; D013440:Sulfides
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000069444:Omalizumab; C093875:montelukast; D011241:Prednisone